Top ▲
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 417 | 5q23.1 | LOX | lysyl oxidase | |
| Mouse | - | 411 | 18 28.22 cM | Lox | lysyl oxidase | |
| Rat | - | 411 | 18q11 | Lox | lysyl oxidase | |
| Gene and Protein Information Comments | ||||||
| Alternative splicing of the human gene results in multiple transcript variants, the longest of which encodes the preproprotein that is post-translationally processed to generate a regulatory propeptide and the mature enzyme. | ||||||
| Previous and Unofficial Names |
| protein-lysine 6-oxidase |
| Database Links |
|
| Alphafold | P28300 (Hs), P28301 (Mm) |
| BRENDA | 1.4.3.13 |
| ChEMBL Target | CHEMBL2249 (Hs), CHEMBL4523209 (Mm) |
| Ensembl Gene | ENSG00000113083 (Hs), ENSMUSG00000024529 (Mm), ENSRNOG00000014426 (Rn) |
| Entrez Gene | 4015 (Hs), 16948 (Mm), 24914 (Rn) |
| Human Protein Atlas | ENSG00000113083 (Hs) |
| KEGG Enzyme | 1.4.3.13 |
| KEGG Gene | hsa:4015 (Hs), mmu:16948 (Mm), rno:24914 (Rn) |
| OMIM | 153455 (Hs) |
| Pharos | P28300 (Hs) |
| RefSeq Nucleotide | NM_002317 (Hs), NM_010728 (Mm), 148747377 (Mm), NM_017061 (Rn) |
| RefSeq Protein | NP_002308 (Hs), NP_034858 (Mm), NP_058757 (Rn) |
| UniProtKB | P28300 (Hs), P28301 (Mm) |
| Wikipedia | LOX (Hs) |
| Enzyme Reaction |
||||
|
||||
Download all structure-activity data for this target as a CSV file 
| Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immuno Process Associations | ||
|
||
|
||
|
||
|
| Gene Expression and Pathophysiology Comments | |
| Mutations in the LOX gene are associated with a predisposition to thoracic aortic aneurysms and dissections [1]. Experimental evidence shows that mutant LOX proteins do not transit to the Golgi, do not have copper incorporated, and hence the proteins do not become catalytically active [2]. So, the LOX loss-of-function is due to a secretion defect rather than to a gross protein structural deformity. |
1. Guo DC, Regalado ES, Gong L, Duan X, Santos-Cortez RL, Arnaud P, Ren Z, Cai B, Hostetler EM, Moran R et al.. (2016) LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections. Circ Res, 118 (6): 928-34. [PMID:26838787]
2. Lee VS, Halabi CM, Broekelmann TJ, Trackman PC, Stitziel NO, Mecham RP. (2019) Intracellular retention of mutant lysyl oxidase leads to aortic dilation in response to increased hemodynamic stress. JCI Insight, 5. DOI: 10.1172/jci.insight.127748 [PMID:31211696]
3. Leung L, Niculescu-Duvaz D, Smithen D, Lopes F, Callens C, McLeary R, Saturno G, Davies L, Aljarah M, Brown M et al.. (2019) Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships. J Med Chem, 62 (12): 5863-5884. [PMID:31070916]
4. Smithen DA, Leung LMH, Challinor M, Lawrence R, Tang H, Niculescu-Duvaz D, Pearce SP, Mcleary R, Lopes F, Aljarah M et al.. (2020) 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth. J Med Chem, 63 (5): 2308-2324. [PMID:31430136]
1.4.3.13 Lysyl oxidases: lysyl oxidase. Last modified on 11/09/2019. Accessed on 20/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3097.
